Sun's takeover of Ranbaxy may hurt competition: CCI

Tags: News
India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.

Sun and Ranbaxy have been asked by the regulator to publish details of the deal within 10 working days on their websites as well as in four national newspapers. The CCI also sought comments or objections from the public on the proposed deal.

Sun Pharma agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd to create the world's fifth-largest maker of generic drugs. Both companies have previously said they expect to complete the deal by December.

EDITORIAL OF THE DAY

  • Air India is a reminder that government should not dilly-dally on tough decisions

    Finance minister Arun Jaitley recently hinted that the government was open to selling its stake in perennially loss making national carrier, Air India

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Freedom Files : Creating a communal cleave

The Nawab of Bhopal Sir Hafiz Hamidullah Khan, saboteur ...

Gautam Datt

Cattle cauldron simmers: Govt mulling order rework

Ban on sale of cattle for slaughter at animal markets ...

Rajgopal Nidamboor

Live life to its fullest potential

Life is full of charm. Yet, we don’t often discern ...